Nebenwirkungen · Mynzepli
MYNZEPLI 40 mg/mL solution for injection in pre-filled syringe. · Abschnitt 4.8 · PDF-Seite 8
HOS-152985 · Präparat HOS-100883
Arterial thromboembolic events (ATEs) are adverse events potentially related to systemic VEGF inhibition. There is a theoretical risk of arterial thromboembolic events, including stroke and myocardial infarction, following intravitreal use of VEGF inhibitors. A low incidence rate of arterial thromboembolic events was observed in the aflibercept clinical trials in patients with AMD, DME, RVO, myopic CNV and ROP. Across indications no notable difference between the groups treated with aflibercept and the respective comparator groups were observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T10:50:00Z · SHA-256 72096a4ce74cd4ff14b17fa758b217d2887b3ffc80bad5a04b9cb6f329b0f1df · Passage 52d3f3faf3fbdcd1c5e9a112ef3d4b3c612bd5491e87d792803f2992942fd9d0 · Zeichen 4687–5238 im Abschnitt